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Heart developmentThe sinoatrial node (SAN), functionally known as the pacemaker, regulates the cardiac rhythm or heartbeat.
Several genes are expressed in thedevelopingSANand formagenetic network regulating the fateof the SANcells.
The short stature homeobox gene Shox2 is an important player in the SAN genetic network by regulating the
expression of different cardiac conduction molecular markers including the early cardiac differentiation marker
Nkx2.5. Here we report that the expression patterns of Shox2 and Nkx2.5 are mutually exclusive from the earliest
stages of the venous pole and the SAN formation.We show that tissue speciﬁc ectopic expression of Shox2 in the
developingmouseheart downregulates the expressionofNkx2.5 and causes cardiacmalformations; however, it is
not sufﬁcient to induce a SAN cell fate switch in the working myocardium. On the other hand, tissue speciﬁc
overexpression ofNkx2.5 in the heart leads to severe hypoplasia of the SAN and the venous valves, dis-regulation
of the SAN genetic network, and change of the SAN cell fate into working myocardium, and causes embryonic
lethality, recapitulating the phenotypes including bradycardia observed in Shox2−/− mutants. These results
indicate that Nkx2.5 activity is detrimental to the normal formation of the SAN. Taken together, our results
demonstrate that Shox2 downregulation of Nkx2.5 is essential for the proper development of the SAN and that
Shox2 functions to shield the SAN from becoming working myocardium by acting upstream of Nkx2.5.+1 504 865 6785.
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The heart is the ﬁrst functional organ to form during embryonic
development, from being a cluster of cells with intrinsic beating
capacity, to an organized pump. The rhythm of the heartbeat is
regulated by the sinoatrial node (SAN), functionally known as the
cardiac pacemaker. In the mouse embryos, the developing heart, as a
straight cardiac tube at embryonic day 8 (E8.0), beats irregularly as
every cell contracts autonomously. As the SAN develops the
embryonic heartbeat becomes regular and organized. By around
E9.0 the heartbeat becomes organized with a caudal to cranial
peristaltic movement and the SAN, functionally, resembles themature
pacemaker (Nishii and Shibata, 2006; Van Mierop, 1967). Although
the SAN has been intensely studied in its physiology and anatomy, its
genetic regulation and molecular interactions during the develop-
ment of the SAN remain elusive. Previous studies have shown the
involvement of several genes in a genetic network regulating SAN
formation and function, including Hcn4, Tbx3, Tbx5, Nkx2.5 and Shox2
(Blaschke et al., 2007; Espinoza-Lewis et al., 2009; Hoogaars et al.,
2007; Mommersteeg et al., 2007; Puskaric et al., 2010). The hyperpolarization-gated cyclic nucleotide cation-activated channel Hcn4, a
SAN speciﬁc molecular marker (Moosmang et al., 2001; Santoro and
Tibbs, 1999), is expressed as early as E7.5 inmouse embryo, initially in
the sinus horns of the sinus venosus, and becomes restricted to the
SAN by E12.5 (García-Frigola et al., 2003). Hcn4 mutations result in
embryonic lethality between E9.5 and E10 due to a failure in the
formation of a mature pacemaker (Stieber et al., 2003). The T-box
gene Tbx3 is expressed in the cardiac conduction system, including the
SAN (Hoogaars et al., 2004). Mutations in Tbx3 in themouse have been
shown to be related to limb andmammary gland defects and cause late
embryonic lethality due to cardiovascular defects (Davenport et al.,
2003). Connexin 40 (Cx40), encoding a high conductivity gap junction
protein, and Nppa (also known as Atrial Natriuretic Factor — ANF), a
chamber differentiation marker, are direct targets of Tbx3 (Hoogaars et
al., 2004) and their expression patterns aremutually exclusive to that of
Tbx3 in theheart. Theexpressionof bothCx40 andNppa is excluded from
the SAN(Gaussin, 2004; Soufan et al., 2004; Stennard andHarvey, 2005;
Van Kempen et al., 1996). Interestingly, overexpression of Tbx3 in the
developing mouse heart results in the ectopic formation of pacemaker
foci in the atrial muscle, demonstrated by the ectopic expression of
Hcn4, alongwith thedown-regulation of Cx40 andNppa, and by the shift
in the electrical signature of the atria to resemble that of the pacemaker
(Hoogaars et al., 2007). The cardiac differentiation marker Nkx2.5 is
expressed as early as the cardiac crescent formation stage (Komuro and
Izumo, 1993;Moses et al., 2001); however, it is not expressed in the SAN
(Kasahara et al., 1998). Nkx2.5 ablation in the mouse results in early
embryonic lethality due to defects in the differentiation of the cardiac
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ciency and point mutations in humans result in arrhythmias and
atrioventricular conduction deﬁciencies (Benson et al., 1999; Schott
et al., 1998; Watanabe et al., 2002). Co-overexpression of Nkx2.5 and
Gata4 in cultured rat ventricular myocytes induces an electrical nodal
phenotype by regulating the expression of voltage gated Ca2+ channels
(Wanget al., 2007). Recently, the short staturehomeoboxgene Shox2has
been shown to be expressed in the SAN in a very restricted and speciﬁc
manner as early as E8.5 in the mouse embryo (Blaschke et al., 2007;
Espinoza-Lewis et al., 2009; Semina et al., 1998). Shox2 null mutation
results in embryonic lethality at around E11.5 due to cardiovascular
defects related speciﬁcally to a failure in thedifferentiationof the SANand
a reduced pacemaker function (Blaschke et al., 2007; Espinoza-Lewis et
al., 2009). Additionally, Shox2mutation disrupts the SANgenetic network
resulting in the down-regulation of Tbx3 and Hcn4, and the ectopic
expression of Cx40,Nppa andNkx2.5 in this region (Espinoza-Lewis et al.,
2009). On the other hand, overexpression of Shox2 in cell cultures aswell
as inXenopusembryos results in thedownregulationofNkx2.5expression
and activity (Espinoza-Lewis et al., 2009), indicating regulation of Nkx2.5
expression by Shox2. It was shown recently that Shox2 mediates Tbx5
activity by regulating Bmp4 expression in the SAN (Puskaric et al., 2010).
While an essential role for Shox2 in the SAN formation has been
demonstrated (Blaschke et al., 2007; Espinoza-Lewis et al., 2009), it
remains unknown if the ectopic Nkx2.5 expression in the SAN region
of Shox2 mutants is the resultant or causative of the failed SAN
formation. To address this question, we created conditional transgenic
mice bearing tissue speciﬁc overexpression of Nkx2.5 in the heart
including the SAN. We also generated conditional transgenic mice
that overexpress Shox2 in the developing heart in order to establish
whether Shox2 expression in the working myocardium is sufﬁcient to
induce a cell fate shift similar to that exerted by Tbx3 (Hoogaars et al.,
2007). We report here that although overexpression of Shox2 in the
developing heart caused a downregulation of Nkx2.5 expression and
leads to cardiac malformation, ectopic SAN-like structures were not
observed, indicating an insufﬁciency of Shox2 expression to induce a
SNA formation. In contrast, ectopic Nkx2.5 expression in the SAN on
wild type background produced SAN defects identical to that found in
Shox2 mutants. We conclude that Shox2 is indeed able to repress
Nkx2.5 expression in the developing heart, and the repression of
Nkx2.5 by Shox2 in the SAN protects the SAN cells within this domain
from following the working myocardial fate.Fig. 1. Shox2 and Nkx2.5 conditional overexpression transgenic constructs and genotyping. (
Cre, Shox2CO and Nkx2-5CO transgenic alleles (arrows represent the relative positions of the p
and STOP-Shox2 or STOP-Nkx2-5 (Lane 2) single transgenic mice; and a Shox2CO or Nkx2-5CO d
staining in an E10.5 cTnt-Cre;R26R double transgenic embryo showing cTnt-Cre cardiac speciﬁ
points to the SAN region and arrowheads point to the sinus valves.Materials and methods
Animals and embryos
To generate Shox2 and Nkx2.5 conditional transgenic mice, the 1.6-
kb loxP-ﬂanked transcriptional STOP cassette sequence from the
pBS302 vector was excised by NotI, blunt-end ﬁlled, gel puriﬁed and
ligated into the blunt-end ﬁlled EcoRI site within the pMES vector to
produce the pMES-STOP vector. Second, the mouse Shox2a or Nkx2.5
coding sequence was ampliﬁed by PCR using Pfu high ﬁdelity
polymerase (Stratagene) with speciﬁc primers containing EcoRI
restriction site. The Shox2a or Nkx2.5 coding sequence was digested
with EcoRI and ligated into the pMES-STOP vector to produce pMES-
STOP-Shox2a (STOP-Shox2) or pMES-STOP-Nkx2.5 (STOP-Nkx2.5).
Transgenic DNA fragments containing the chicken β-actin/CMV
enhancer promoter, the loxP ﬂanked STOP cassette and Shox2a or
Nkx2.5 coding sequence followed by the IRES2-EGFP sequence and
a rabbit β-globin polyA tail, were released by BciVI as a 6.7-kb
fragment, gel puriﬁed, diluted in injection buffer (5 mM Tris–HCl,
0.1 mM EDTA, pH 7.1), and used for pronuclei injection in Tulane
Transgenic/Knockout facility.
Tissue-speciﬁc overexpression transgenic mice (Shox2CO or
Nkx2.5CO) were obtained by crossing the STOP-Shox2 or STOP-Nkx2.5
mouse lines with the cTnt-Cre transgenic line which speciﬁcally
expresses Cre recombinase in the cardiac tissue including the SAN
(Wang et al., 2000, 2001; Fig. 1). Identiﬁcation of each transgenic line
was performed by PCR using speciﬁc primers. Double transgenic
embryos were identiﬁed by observing the green ﬂuorescence under
UV light, and conﬁrmed by PCR genotyping (Fig. 1). Primers used for
genotyping are given as follows: cTnt-Cre: For. 5′-GGACATGTTCAGG-
GATCGCCAGGCG-3′, Rev. 5′-GCATAACCAGTGAAACAGCATTGCTG-3′;
STOP-Shox2: For. 5′-ACTCCACACAGGCATAGAGTGTC-3′, Rev. 5′-
GCCTCCTTCTTCTCCTTCACTT-3′; STOP-Nkx2.5: For. 5′-CCAGGTTCAG-
GATGTCTTTGAC-3′, Rev. 5′-ACTCCACACAGGCATAGAGTGTC-3′.
Histology, in situ hybridization, immunohistochemistry, BrdU labeling
and TUNEL assay
Embryos were harvested in DEPC-treated PBS and ﬁxed in 4%
PFA in DEPC-PBS overnight at 4 °C, dehydrated through an ethanol
series, cleared in xylene and embedded in parafﬁn wax. SamplesA, D) Graphic representation of the genetic structure of STOP-Shox2, STOP-Nkx2-5, cTnt-
rimer pairs used for genotyping). (B, E) PCR results for genotyping of cTnt-Cre (Lane 1)
ouble transgenic mouse (Lane 3). LaneM is a 100 bp DNA ladder (Invitrogen). (C) X-gal
c activity in whole embryo staining (red arrow) and in section. Red arrow in the section
361R.A. Espinoza-Lewis et al. / Developmental Biology 356 (2011) 359–369were sectioned at 7 μmforHematoxylin/Eosin staining, and at 10 μmfor
in situ hybridization or immunohistochemical staining. Probes used and
in situ hybridization have been described previously (Alappat et al.,
2005; Espinoza-Lewis et al., 2009). Polyclonal antibody against Nkx2.5
was obtained from Santa Cruz Biotechnology, Inc., and immunohisto-
chemical staining was performed according to the manufacturer's
instruction. Cell proliferation rate was determined by in vivo BrdU
labeling using a BrdU Labeling Solution and Staining Kit following the
manufacturer's instruction (Zymed Lab., Invitrogen, CA), and TUNEL
assays were carried out by using a Cell Death Detection Kit (Roche
Applied Sciences, IN), as previously described (Alappat et al., 2005; Yu
et al., 2005). In order to have consistent results, all the experimentswere
done at least three times, including in situ hybridization, BrdU labeling,
and TUNEL assays. To determine cell proliferation rate, BrdU-positive
cells were counted and presented as percentage of total cells within a
deﬁned area. Nine sections from three individual samples of either wild
type or mutant were counted and applied to statistical calculation, and
the Student's t-test was used to determine statistical signiﬁcance.
Embryonic heartbeat rate measurement
Embryonic heartbeat rate was measured as described previously
(Espinoza-Lewis et al., 2009; Stieber et al., 2003). Brieﬂy, E10.5
embryos were harvested in pre-warmed ADS buffer, the hearts were
isolated and cultured in DMEM supplemented with 10% FBS at 37 °C
with 10% CO2 for 24 h. Each heart was then placed under inverted
scope and counted for beats for 10 s three times. The counts were
converted to heartbeat per minute. The Student's t-test was used to
determine statistical signiﬁcance of heartbeat rate between the wild
type controls and Nkx2.5-overexpressing mice.
Quantitative real-time PCR
Staged individual embryonic (E10.5, E12.5) and P1mouse heart was
isolated and subjected to mRNA extraction with Trizol (Invitrogen).
Isolated mRNAs was further subjected to reverse transcription. TaqMan
real-time PCR was used to quantify expression levels of Nkx2.5 in each
wild type and Shox2-overexpressing heart using commercially availableE9
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Fig. 2. Shox2 and Nkx2.5 expression patterns are mutually exclusive. Expression patterns of
junction between the common cardinal vein and the primitive atrium at E9.0 (A) and in the
working myocardium in a complementary pattern to that of Shox2 at both stages (B, D).
expression regions. V, ventricle; Rh, right horn of sinus venosus; SV, sinus venosus.primers (Mm01309813_S1 forNkx2.5, fromApplied Biosystems).Gapdh
(Mm99999915_g1, from Applied Biosystems) was included as endoge-
nous control for normalization. The comparative Ct (2−ΔΔCT) method
was used for calculation (Livak and Schmittgen, 2001).Results
Expression of Shox2 and Nkx2.5 is mutually exclusive from early stage of
heart formation
During early heart development, Shox2 exhibits a speciﬁc and
restricted expression pattern in the prospective SAN region starting at
E8.5, and later in the SAN and sinus valves (Blaschke et al., 2007;
Espinoza-Lewis et al., 2009). An Nkx2.5− and Tbx18+ SAN progenitor
cell population is meanwhile recruited to constitute the venous pole
of the heart (Christoffels et al., 2006). These observations suggest an
early exclusive expression pattern of Shox2 and Nkx2.5. Following this
rationale along with the previous report of ectopic expression of
Nkx2.5 in the SAN region in the Shox2−/− embryonic heart, we
analyzed the expression patterns of Shox2 and Nkx2.5 in the
embryonic heart from E9.0, before the formation of the venous
return, to E15.5. We found that Shox2 is expressed at the junction
formed by the common cardinal vein and the primitive atrial chamber
while Nkx2-5 is expressed in the working myocardium excluding the
venous-atrial junction at E9.0 (Figs. 2A, B). At E9.5, at the beginning of
the SAN formation, Shox2 is expressed in the prospective SAN and
sinus valves, given that the SAN region is not completely shifted to the
right side, a region of expression in the left sinus horns is still visible;
while Nkx2.5 maintains an expression pattern including the working
myocardium only (Figs. 2C, D). In the following developmental stages
at E11.5, E13.5, and E15.5, Shox2 and Nkx2.5 maintain mutually
exclusive expression patterns in the SAN (Supple. Fig. 1; Blaschke
et al., 2007; Espinoza-Lewis et al., 2009). These results indicate an
absence of Nkx2.5 expression in the prospective SAN region from the
earliest stages of the venous pole formation complementary to that of
Shox2, and these two genes maintain their mutual exclusive
expression patterns in the SAN until at least E15.5.B
D
V
SV
Rh
V
Nkx2-5
Shox2 (A, C) and Nkx2.5 (B, D) in the early embryonic heart. Shox2 is expressed at the
SAN and venous valves regions at E9.5 (C). Nkx2.5 is clearly expressed in the forming
Black arrows point to Shox2 expressing domains, and red arrows point to the Nkx2.5
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We have reported previously that overexpression of Shox2 in
Xenopus embryos results in cardiac defects in addition to the
downregulation of Nkx2.5 expression (Espinoza-Lewis et al., 2009).
Direct transgenic overexpression of Shox2 in the heart caused early
embryonic lethality in mice, preventing detailed analysis of the effect
of Shox2 overexpression on the mouse developing heart (Espinoza-
Lewis et al., 2009). Thus a conditional transgenic approach became
necessary in order to circumvent this problem. Since it was
determined previously that Shox2a isoform is expressed in the
mouse developing heart (Espinoza-Lewis et al., 2009), we chose to
use Shox2a as the transgene.
Five founders positive for the STOP-Shox2 transgene were obtained
and all gave germline transmission. Tissue speciﬁc overexpression of
Shox2 in the heart was achieved by crossing the STOP-Shox2 transgenic
line with the cTnt-Cre transgenic line; the latter expresses the Cre
recombinase from E7.5 in the cardiac crescent and completely recom-
bines loxP-ﬂanked DNA by E10.5 in the mouse embryo (Jiao et al., 2003;
Wang et al., 2000, 2001) (Fig. 1C). Thus, ectopic Shox2 expression was
expected from the early stages of heart formation. Crossings of the
respective linewith the cTnt-Cre transgenic line showed variability in the
expression of Shox2 observed by the expression of the EGFP protein tag
and conﬁrmed by in situ hybridization (Fig. 3). Three lines, 1805, 1795
and 1794, expressed Shox2 uniformly; another two, 1808 and 1811,
expressed it in a spotty manner. Histological analyses of E10.5 doubleSh
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Fig. 3.Overexpression of Shox2 in themouse heart. Comparison between wild type (A) and tw
expression in two Shox2CO mouse lines is evidenced by the expression of EGFP protein ta
expression in working myocardium in both transgenic lines (G, K) compared to the wild
embryos reveals ventricular wall and trabeculation defects (asterisks). Scale bars representtransgenic (Shox2CO) embryos obtained from individual founder lines
revealed neither a cardiac patterning defect nor heart formation
impairment. However, thinning of the ventricular wall and less
ventricular trabeculation was observed (Fig. 3H) when compared to
wild type controls (Fig. 3D).Nevertheless, thinning of the ventricularwall
and the fewer ventricular trabeculae defects were more severe in
embryos obtained from founder transgenic lines with spotty Shox2
overexpression (Fig. 3). Additionally, the survival ratios observed in each
transgenic line differed;Mendelian ratios were skewed in lines 1805 and
1811, while they were not in the other transgenic lines. Nevertheless,
results for embryonic histological analyses are shown for two represen-
tative lines (Fig. 3).
Similarly, gross anatomical and histological analyses of the Shox2CO
transgenic heart at postnatal day 1 (P1) revealed a signiﬁcantly smaller
and round shaped heart when compared to the wild type littermate
controls (Fig. 4). All four chambers formed but the apex of the heart did
not exist. In coronal histological sections these hearts show a relative
thicker left ventricular compact zone and a thinner right ventricular
compact zone; additionally, fewer and shorter ventricular trabec-
ulae were also observed, as compared to the wild type controls
(Figs. 4C, C′, C″). The atria appear normal; however, they are smaller
when compared to wild type hearts. We subsequently investigated the
effect of Shox2 overexpression on Nkx2.5 expression in the transgenic
heart by immunohistochemical staining using a polyclonal antibody
against Nkx2.5. The results showed an overall reduction in Nkx2.5
expression in the transgenic heart, including the compact zone and the*
*
*
.5
D
H
L
o Shox2CO (E, I) lines under visible light shows nomorphological differences. Transgene
g under UV light (B, F, J). (C, G, K) In situ hybridization demonstrates Shox2 ectopic
type (C). (D, H, L) Histological comparison between wild type (D) and Shox2CO (H, L)
1-mm in panels A, B, E, F, I, J, and 100-μm in panels C, D, G, H, K, L.
Fig. 4. Overexpression of Shox2 in the mouse heart results in downregulation of Nkx2.5 and cardiac malformation. Gross morphological defects are observed in Shox2CO transgenic
hearts (A′, A″) when compared to the control (A) at postnatal day 1 (P1). Transgene expression is evidenced by green ﬂuorescence under UV light in the Shox2CO heart of two
independent lines (B′, B″), but not in the control (B). Coronal histological sections show cardiac phenotype in two Shox2CO transgenic lines (C′, C″) when compared to the wild type
littermate control (C), including size of the ventricular chambers as well as the shape of the entire heart (B, B′, B″). A thicker left ventricular wall and a thinner right ventricular wall
(C′, C″) compared to the control (C) are observed. Expression of Nkx2.5 is down-regulated in the compact zone as well as in the ventricular trabeculae in the both Shox2CO transgenic
lines (D′, D″, E′, E″) when compared to the control (D, E). (F) Real-time RT-PCR assays show transcriptional reduction of Nkx2.5 expression in the heart from both Shox2CO transgenic
lines at E10.5, E12.5 and P1 (n=4 for all genotypes and stages). In all ﬁgures right ventricle is to the right. Scale bars represent 1-mm in columns A, B, and C, and 75-μm in column E.
Column E represents high magniﬁcation of the boxed area column D.
363R.A. Espinoza-Lewis et al. / Developmental Biology 356 (2011) 359–369ventricular trabeculae (Figs. 4E, E′, E″, and insets). To further conﬁrm
this in vivo repression ofNkx2.5 expression by overexpressed Shox2, we
conducted real-time RT-PCR assays to quantify the expression levels of
Nkx2.5 in the developing heart of wild type and both Shox2 transgenic
lines (lines 1794 and 1811). As shown in Fig. 4F, Nkx2.5 transcriptional
expression level is reduced about 35% in the heart of line1794and about45% in line 1811 at E10.5, E12.5 and P1when compared to thewild type
controls, respectively. These results indicate that overexpression of
Shox2 does not affect the early differentiation of cardiomyocytes. Shox2
is able to repress, although partially, Nkx2.5 expression in the
myocardium in vivo, which is consistent with our previous report that
Shox2 partially represses the transcriptional activity of themouseNkx2.5
364 R.A. Espinoza-Lewis et al. / Developmental Biology 356 (2011) 359–369promoter in cell cultures in neonatal rat cardiomyocytes and H9c2 cell
line (Espinoza-Lewis et al., 2009). However, late development defects
might be attributable to the low level of Nkx2.5 expression.
To determine if Shox2 over/ectopic expression in the heart could result
in ectopic formation of SAN-like foci, as it was observed in Tbx3
overexpressingheart (Hoogaars et al., 2007),we examined theexpression
of the SAN markers Tbx3 and Hcn4 in E13.5 Shox2CO heart. No ectopic
expression of Tbx3 and Hcn4 was observed in the transgenic heart, as
compared to thewild type control (data not shown), indicating that Shox2
ectopic expression does not induce the formation of ectopic SAN.
Overexpression of Nkx2.5 in the heart results in cardiac abnormalities
and leads to embryonic lethality
To further delineate genetic interactions between Shox2 and
Nkx2.5 and their role in the SAN development, we generated Nkx2.5A
B
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Fig. 5. Overexpression of Nkx2.5 results in cardiac abnormalities including hypoplastic SAN.
embryos. Transgene expression is evidenced by speciﬁc EGFP activity in the heart ofNkx2.5CO
(E, G) and Nkx2-5CO (F, H) embryos at E10.5 (E, F) and at E11.5 (G, H) shows thinning of th
overgrowth (arrowhead) at E10.5 (F) in Nkx2.5CO hearts when compared to wild type con
appears normal at E10.5 (F). Thickened ventricular wall, hypoplastic interventricular (IV) s
and sinus valves (arrows) are observed at E11.5 in Nkx2-5CO embryonic hearts (H) when com
cell proliferation in the SAN (asterisk) and sinus valves (arrows) in the Nkx2.5CO transgenic
control and Nkx2.5CO heart indicates a signiﬁcant reduction (*: Pb0.005) (K). Measurem
signiﬁcantly reduced heartbeat rate (**: Pb0.0001) in the heart of Nkx2.5CO transgenic mi
compared to the wild type controls (L). Arrows point to the SAN and sinus valves in panels E
Asterisks (*) are placed to depict ventricular trabeculation in panels F and H, or the SAN in pa
in panels G and H, and 50-μm in panels I and J.conditional transgenic mice (STOP-Nkx2.5) (see Materials and
methods). Pronuclear injection gave seven founders positive for the
STOP-Nkx2.5 transgene. Among them, three founders gave germline
transmission. F1 transgenic mice from each line were crossedwith the
cTnt-Cre line to determine the speciﬁcity and level of transgene
expression. Double transgenic embryos (Nkx2.5CO) from all three lines
presented similarly strong, smooth and consistent expression of the
EGFP tag (Figs. 5C, D). Similar cardiac phenotype was also observed in
double transgenic embryos from all three lines by histological
sections. One of the lines was eventually kept for further analysis.
Cardiac overexpression of Nkx2.5 appears to be embryonically lethal,
since Nkx2-5CO embryos were not found at birth in 4 litters analyzed.
In harvesting of embryos at different stages it was found that 70% of
the double transgenic embryos die between E11.5 and E12.5 and none
of them survive beyond E13.5. Gross anatomy of E10.5 Nkx2.5CO
embryos appeared normal when compared to wild type littermates*
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e ventricular wall and ventricular trabeculation abnormalities, along with AV cushion
trol (E). The morphology of the SAN and sinus valves (arrow) of the transgenic heart
eptum (arrowhead), reduced ventricular trabeculation (asterisk), and hypoplastic SAN
pared to wild type embryos (G). BrdU labeling assays demonstrated a reduced level of
heart (J), as compared to the control (I). A comparison of BrdU positive cells between
ent of beat rate in isolated embryonic hearts at E10.5 after 24 h in culture shows a
ce and triple transgenic mice (cTnt-Cre;Nkx2.5CO;Shox2CO, designated as Triple TG) as
, G, I, and J, arrowheads point to the AV cushion in panel F and the IV septum in panel H.
nels I and J. Scale bars represent 1-mm in panels A–D, 250-μm in panels E and F, 100-μm
365R.A. Espinoza-Lewis et al. / Developmental Biology 356 (2011) 359–369(Figs. 5A, B). Histological analysis of Nkx2.5CO embryos at E10.5 showed
a thinner ventricular wall and trabeculation abnormalities. An over-
growth of the atrioventricular cushion could be observed in some
specimens; however, it is not consistent at this stage. Additionally,
the atrial wall, the SAN and the venous valves showed no obvious
structural differences when compared to the wild type controls
(Figs. 5E, F). At E11.5 obvious structural defects could be observed.
Transgenic embryos presented cardiac edema, characteristics
similar to that observed in Shox2−/− embryos (Blaschke et al.,
2007; Espinoza-Lewis et al., 2009). Histological analysis of the
Nkx2.5CO embryos at this stage showed an apparent thickening of
the ventricular wall, thickening of the ventricular trabeculae,
hypoplastic interventricular septum, as well as hypoplastic sinus
valves and SAN that mimic that observed in Shox2 mutant mice
(Figs. 5G, H; Espinoza-Lewis et al., 2009).
To elucidate the cellular process involved in the hypoplasia of the
SAN and the venous valves, we performed TUNEL assays to measure
cell apoptosis and BrdU incorporation and staining to measure cell
proliferation rates in E10.75–E11.0 embryos. Results obtained indicate
that the level of cellular apoptosis is unchanged in the Nkx2.5CO
embryos as compared to the wild type littermates (data not shown).
However, there was a signiﬁcant reduction (Pb0.005) in the
percentage of proliferating cells (Fig. 5K) in the regions comprising
the SAN and the sinus venous valves in the Nkx2.5CO embryonic heart
(Fig. 5J) when compared to the wild type (Fig. 5I).
Given the fact that the Nkx2.5CO heart and Shox2−/− heart exhibit
similar defects in the SAN and sinus valves and that Shox2−/− embryos
exhibit bradycardia (Espinoza-Lewis et al., 2009), we set to measure the
heartbeat rate, an indication of the pacemaker function in isolated
embryonic heart of Nkx2.5CO mice. We harvested heart from E10.5
Nkx2.5CO embryos (n=6) and their wild type littermates (n=11), and
cultured individual heart in vitro for 24 h prior to counting heartbeats.
Our results demonstrate that like Shox2−/− heart, Nkx2.5CO hearts
presented a much slower heartbeat rate (56±2.6 bpm) as compared to
the controls (136±8.3 bpm) (Fig. 5L). We further measured the
heartbeat rate in isolated embryonic hearts (n=4) from E10.5 mice
carrying triple transgenes (cTnt-Cre;Nkx2.5CO;Shox2CO), which overex-
pressed both Nkx2.5 and Shox2 in the heart. Similar to the Shox2−/− and
Nkx2.5CO hearts, the triple transgenic hearts also exhibited a bradycardiac
phenotype (57±4.9 bpm) (Fig. 5L), indicating that even under the
situation of Shox2 overexpression in the heart including the SAN, ectopic
Nkx2.5 expression in the SAN still alters the function of pacemaker. These
observations provide evidence for a dysfunctional pacemaker in addition
to the malformed SAN in Nkx2.5CO mice.
Ectopic expression of Nkx2.5 in the SAN disrupts the SAN genetic regulatory
network
The SAN and pacemaker region in developing embryo have been
generally determined by a combination of the expression or lack thereof
of severalmolecules to deﬁne its boundaries (Soufanet al., 2004).Nkx2.5
is not expressed in theSANduringnormal heart development (Kasahara
et al., 1998). In the Shox2−/− hearts, the SAN cells fail to differentiate,
accompanied by the ectopic activation of Nkx2.5 (Blaschke et al., 2007;
Espinoza-Lewis et al., 2009).However, it remainedunclear if this ectopic
activation of Nkx2.5 in the Shox2−/− SAN is the resultant or causative of
the failure of the SAN formation. As shown in Fig. 1C, the cTnt-Cre
transgenic mouse expresses Cre recombinase that activates reporter
gene expression in the entire heart including the SAN at E10.5. We
examined Nkx2.5 expression by immunohistochemistry in theNkx2.5CO
heart. In addition to a stronger immunostaining level of Nkx2.5 protein
in the working myocardium, we indeed observed an ectopic Nkx2.5
immunoactivity in the SAN, as compared to the wild type control
samples (Figs. 6A, B). Since Nkx2.5CO embryos exhibit hypoplastic SAN
and sinus valves, we performed in situ hybridization to determine the
expression patterns of the SAN genetic network genes including Shox2,Tbx3, andHcn4. At E10.5, despite of anunaltered Shox2 expression in the
transgenic SAN, we observed a down-regulation of Tbx3, and a reduced
but not absent Hcn4 expression (Fig. 6), indicating that Shox2 does not
regulate the expression of Tbx3 andHcn4 directly in the SAN, consistent
with the observation that Shox2 ectopic expression does not induce
ectopic expression of Tbx3 and Hcn4 in the developing heart. At E11.5
when the hypoplastic SAN defect becomes severe, the expression of
both Tbx3 andHcn4was signiﬁcantly down-regulated in the SAN region
of the transgenic embryos, as compared to the wild type controls
(Fig. 7). Meanwhile, Nppa, a chamber differentiation marker, and Cx40
whosehigh expression level represents areasof conductivity outside the
SAN region, exhibit ectopic activation in the transgenic SAN and sinus
valves, as compared to the wild type controls (Fig. 7). Interestingly,
Shox2 expression was inactivated in the SAN region and sinus valves at
this stage (Fig. 7). This inhibition of Shox2 expression is likely resulted
from the failed SAN formation and cell fate change. This is because at
E10.5 right before the hypoplastic SAN and sinus valves become
discernible, Shox2 expression remains unaltered while Tbx3 and Hcn4
expressions begin to become reduced or down-regulated. Shox2
expression becomes inactivated in the SAN region at E11.5 when the
SAN cells change their fate toworkingmyocardium, as evidenced by the
absence of SAN markers and ectopic activation of chamber markers.
Nevertheless, our results demonstrate that cardiomyocyte differentia-
tion is not affected by the overexpression of Nkx2.5, conﬁrming the
results obtained in the chicken embryonic heart infected by Nkx2.5-
expressing adenoviruses (Gourdie et al., 1995). Ectopic Nkx2.5 expres-
sion in the SAN region, even in the Shox2wild type background, disrupts
the expression of the SAN genetic regulatory genes and alters the fate of
the SAN cells.
Discussion
Histological studies (Challice and Virágh, 1974; Van Mierop and
Gessner, 1970) and molecular analyses have indicated that the SAN
cells are recruited into the venous pole of the heart. Nkx2.5 is
expressed from early stages of cardiac development (Komuro and
Izumo, 1993) and is important in the formation of this organ (Lyons
et al., 1995; Tanaka et al., 1999) including the peripheral conduction
system (Gourdie et al., 1995; Meysen et al., 2007). However, Nkx2.5 is
dispensable for the formation of the SAN and the cardiac pacemaker.
The ﬁrst indication for this phenomenon is that Nkx2.5 is not
expressed in this structure (Kasahara et al., 1998); second, progenitor
cells for the SAN have been reported to be Nkx2.5 negative and Tbx18
positive, and constitute a third cardiac population (Christoffels et al.,
2006). Thus, Nkx2.5 must be repressed in the initial steps of cardiac
development for the normal formation of the SAN. Recently, it has
been shown that Shox2 acts as an Nkx2.5 repressor. A null mutation in
the Shox2 gene resulted in the ectopic expression of Nkx2.5 in the SAN
region and other cardiac molecular markers were dis-regulated
(Blaschke et al., 2007; Espinoza-Lewis et al., 2009). Our present
studies demonstrate that the expression patterns of Nkx2.5 and Shox2
are mutually exclusive from the early stages of SAN formation (Fig. 2;
Suppl. Fig. 1), further suggesting that the lack ofNkx2.5 expression in the
SAN is a result of Shox2 activity. Gain-of-function studies in Xenopus
embryos, aswell as in cell cultures, revealed that Shox2 is able to repress
the expression of Nkx2.5 (Espinoza-Lewis et al., 2009). In Xenopus
embryos, overexpression of Shox2 causes the down-regulation of
XNkx2.5 in the ventral middle section, the cardiac region. The heart, at
later stages of development, is small and tubular (Espinoza-Lewis
et al., 2009). Here, by using conditional transgenic approach, we
further demonstrate that, in the mouse embryo, ectopic expression
of Shox2 in the heart results in down-regulation of Nkx2.5 in
addition to cardiac malformation.
Despite the down-regulation of Nkx2.5 expression and the cardiac
defects, the heart in Shox2-overexpressing mice is still functioning,
which differs from the results obtained in previous Nkx2.5 loss-of-
Fig. 6. Cardiac conditional overexpression of Nkx2.5 results in alteration of the SAN regulatory genetic network. Expression patterns of Nkx2.5 (A, B); Shox2 (C, D); Hcn4 (E, F); and
Tbx3 (G, H) at E10.5 in wild type and Nkx2.5CO embryonic hearts are shown. Expression of Nkx2.5 is ectopically expressed in the SAN cells (arrows; arrowheads in insets) of the
double transgenic heart (B), as compared to the control (A). Expression of Shox2 remains unaltered in the Nkx2.5CO embryonic heart (D) compared to the littermate control
(C). Expression of the pacemaker channel Hcn4 is reduced in the SAN of Nkx2.5CO heart (F) when compared to the control (E), however, it is not absent. Tbx3 expression is speciﬁcally
down-regulated in the SAN region of Nkx2.5CO embryonic heart (H) when compared to the wild type control (G). Arrows point to the location of the SAN; scale bars represent 50-μm.
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negative derivatives of XNkx2.5 in frog embryos resulted in loss of
mesodermal cardiac progenitor cells; anti-nkx2.5 morpholino injec-
tion in zebraﬁsh caused elongation abnormalities of the tubular heart,disorganized atrial cells and an enlarged ventricle; and Nkx2.5 null
mutation in mice resulted in defects in cardiac differentiation and the
formation of an abnormal, small and tubular heart (Fu et al., 1998;
Tanaka et al., 1999; Targoff et al., 2008). Two factors could be considered
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Fig. 7. Fate change of the SAN cells in the Nkx2.5CO transgenic heart. (A–F) At E11.5, the
expression of Shox2,Hcn4, and Tbx3 is completely repressed in the SAN and sinus valves of
the Nkx2.5CO heart (B, D, F), as compared to their expression in the control (A, C, E). (G–J)
On the other hand, ectopic expression of Cx40 and Nppa is observed in the SAN and the
sinus valves in theNkx2-5CO hearts (H, J) compared to thewild type controls (G, I). Arrows
point to the location of the SAN; red arrowheads point to the sinus valves. Scale bars
represent 50-μm.
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overexpression is conditionally achieved by the cTnt-Cre transgenic line
which shows Cre activity from E7.5, but does not fully recombine loxP-ﬂanked DNA until E10.5 (Jiao et al., 2003;Wang et al., 2000, 2001), thus
giving a time window for Nkx2.5 function to allow for the early
differentiation of cardiomyocytes. This is consistent with previous
reports that Nkx2.5 null mutation at early stages results in embryonic
lethality due to cardiac abnormalities (Lyons et al., 1995; Tanaka et al.,
1999), while deletion of Nkx2.5 at later stages results in cardiac
malformations, cardiac conduction abnormalities and death, but only
in juvenile or adult stages (Jay et al., 2005; Kasahara et al., 2003;
Pashmforoush et al., 2004). 2) Shox2 is not able to repress Nkx2.5
expression completely in cardiomyocytes. This conclusion is supported
by both in vitro and in vivo studies. Our previous cell culture assays have
shown that Shox2 partially represses the activity of the mouse Nkx2.5
promoter (Espinoza-Lewis et al., 2009), and thepresent studyusing real-
time PCR demonstrates an about 40% transcriptional repression of
Nkx2.5 expression in the Shox2-overexpressing heart. It is known that
homeodomain-containing proteins exert transcriptional activities either
by binding directly to the DNA or by binding to other proteins and act as
co-factors (Del Bene and Wittbrodt, 2005). In order to completely
repressNkx2.5 expression, Shox2may have to interact with other factors
that are not present in the working myocardium. The lack of
ectopic SAN-like structure in Shox2-overexpressing heart could be
explained as insufﬁciency of Shox2 expression to induce such a
structure de novo, it could be attributed, at least partially, to the
residual Nkx2.5 expression.
In order to further elucidate the relationship between Shox2 and
Nkx2.5 and the negative effects of Nkx2.5 in the SAN, we over-
expressed Nkx2.5 in the developing heart including the SAN region by
a conditional transgenic approach. Tissue speciﬁc overexpression of
Nkx2.5 (Nkx2.5CO) in the heart results in a phenotype which very
closely resembles the one observed in the Shox2−/− hearts.
Transgenic embryos exhibit cardiac edema and died between E11.5
and E13.0. Histologically, hypoplastic SAN and sinus valves are
observed due to a reduced cell proliferation, in addition to thinning
of the atrial wall at E10.5 and thickening of the ventricular wall at
E11.5, and ventricular trabeculae defects are evident at both stages.
Functionally, Nkx2.5-overexpressing heart presented a signiﬁcantly
reduced heartbeat rate, a pacemaking defect that was also observed in
Shox2mutant heart (Espinoza-Lewis et al., 2009). The thickening of the
ventricular wall and the ventricular trabeculae at E11.5 might be the
result of a compensatory effect due to a malfunctioning SAN, since the
heart is not able to maintain a normal blood ﬂow. However, a direct
effect by Nkx2.5 overexpression is highly possible. While embryonic
overexpression of Nkx2.5 is lethal during embryonic stages (Wakimoto
et al., 2003), postnatal Nkx2.5 overexpression driven by the α-MHC
promoter results in cardiac chamber enlargement, ventricular wall
thinning, disorganization of the cardiomyocyte sarcomere structure
and sudden death due to cardiac conduction defects associated with
the down-regulation of the ventricular conduction Connexin Cx43
(Kasahara et al., 2003). In the Nkx2-5CO embryonic hearts the SAN
genetic program is disturbed, despite of an initial unaltered Shox2
expression. The expression ofHcn4 and Tbx3 is down-regulated, and the
Tbx3 direct targets Nppa and Cx40 are ectopically activated in the SAN
region. Interestingly, the expression of Shox2disappears at E11.5whena
discernible SAN could not be observed. These histological, cellular, and
genetic results are similar to those found in the Shox2−/− embryonic
hearts (Blaschke et al., 2007; Espinoza-Lewis et al., 2009). The loss of
Shox2 expression is likely a result of change in the SANcell fate, but is not
a consequence of transcription repression by the ectopically expressed
Nkx2.5. This is supported by the fact that Nkx2.5 does not repress the
Shox2 promoter activity in a reporter assay in cell culture. Interestingly,
instead of acting as a repressor for Shox2 expression, Nkx2.5 could
actually activate the Shox2 promoter activity (data not shown). These
results are consistentwith a recent report thatNkx2.5 acts cooperatively
with Tbx5 to activate the Shox2 promoter (Puskaric et al., 2010).
Nevertheless, the expression of Nkx2.5 is detrimental to the SAN
formation, even in the wild type background. The expression of Shox2
368 R.A. Espinoza-Lewis et al. / Developmental Biology 356 (2011) 359–369and Hcn4 in the SAN region of Nkx2.5-overexpressing embryos at E10.5
conﬁrms previous remarks that progenitor cells do exist. However, the
SAN fate cannot be maintained and it shifts in favor of the working
myocardium driven by the expression of Nkx2.5, as evidenced by the
complete down-regulation of Tbx3 andHcn4 and the ectopic expression
ofNppa andCx40, themolecularmarkers ofworkingmyocardium.These
observations further support our previous conclusion that the ectopic
Nkx2.5 activation in the Shox2−/− SAN is the causative of the failed SAN
formation.
Taken together, ectopic Shox2 expression is not sufﬁcient to induce
the SAN genetic program and formation of ectopic SAN-like structure
in the developing heart. The Nkx2.5 repression by Shox2 in the
prospective SAN is a necessary process for the normal development
and formation of the SAN. This repressive activity of Shox2 on Nkx2.5
in the SAN facilitates the expression of a genetic program to maintain
the SAN fate and shield it from becoming working atrial myocardium.
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